There's A New Binder On the Block: FDA Approves Patiromer

October 22, 2015

BETHESDA, MD — The US Food and Drug Administration (FDA) has approved a new oral option for reversing hyperkalemia, patiromer. Patiromer is an oral suspension (Veltassa, Relypsa) that has just come out of the phase-2 AMETHYST-DN study, which  showed that daily administration of the potassium-binding agent safely controlled hyperkalemia over a 1 year in patients…
Read more